Clinical trials: Drug Resistance
Type 2 Diabetes
How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics
This study is designed to look at how using glargine insulin with oral diabetes medications and exenatide may improve control of blood sugar levels and weight gain in type 2 diabetics. The main study will last 32 weeks.
- Trial name
- MEXELIN (NCT00667732)
- Testing
- exenatide
- Where
- 3 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Malaria
Studies of a Candidate Aminoquinoline Antimalarial (AQ-13)
This is an initial efficacy study of a candidate antimalarial in human subjects with uncomplicated malaria caused by the most common and most important parasite in Africa (Plasmodium falciparum).
- Trial name
- NCT01614964
- Testing
- AQ-13 Treatment, Coartem Treatment
- Where
- Mali
- Volunteers
- 66 people
- Sponsor
- Tulane University
HIV Infections
Viral Dynamics and Pharmacokinetics of Abacavir and Tenofovir
Once-daily nucleotide/nucleoside reverse transcriptase inhibitor (NtRTI/NRTI) combinations form the backbone of many regimens. Although efficacy data exists between tenofovir and the pyrimidine analogues (i.e.
- Trial name
- NCT00214890
- Testing
- Tenofovir, Abacavir
- Where
- 5 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of California, San Diego
Prostatic Neoplasms
Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-7339-010/KEYLYNK-010)
The purpose of this study is to assess the efficacy and safety of the combination of the polyadenosine 5'-diphosphoribose poly (ADP-ribose) polymerase (PARP) inhibitor olaparib and pembrolizumab in the treatment of participants…
- Trial name
- KEYLYNK-010 (NCT03834519)
- Testing
- Pembrolizumab, Olaparib, Abiraterone acetate
- Where
- 193 sites in United States, Argentina and 18 more
- Volunteers
- 793 people
- Sponsor
- Merck Sharp & Dohme LLC
Gonorrhoea
Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea
This is a multi-center Phase 2 randomized, open-label study in approximately 180 adult male and female subjects, between the ages of 18 and 55, who are in good health and meet all eligibility criteria.
- Trial name
- NCT02257918
- Testing
- AZD0914, Ceftriaxone
- Where
- 5 sites in United States
- Volunteers
- 180 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Highly Drug-resistant Focal Epilepsy
An Open-label Extension Study of UCB0942 in Adult Patients With Highly Drug-resistant Focal Epilepsy
The purpose of study EP0073 is to assess the long-term safety, tolerability, and efficacy during 5 years of treatment with the drug UCB0942 in patients with highly drug-resistant focal epilepsy.
- Trial name
- NCT02625090
- Testing
- UCB0942
- Where
- 15 sites in Belgium, Bulgaria and 4 more
- Volunteers
- 42 people
- Sponsor
- UCB Biopharma SRL
Major Depressive Disorder
Targeting IL-17A for Treatment-Resistant Depression
The proposed study aims to test ixekizumab, a monoclonal antibody (mAb) against interleukin 17A (IL-17A), in patients with treatment-resistant depression (TRD).
- Trial name
- NCT04979910
- Testing
- Ixekizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Metastatic Castration-resistant Prostate Cancer
Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer
Observational study in the routine clinical practice setting to evaluate the short and long term safety profile of Radium-223 in metastatic castration resistant prostate cancer patients and to evaluate the risk of developing…
- Trial name
- REASSURE (NCT02141438)
- Testing
- Radium-223 dichloride (Xofigo, BAY88-8223)
- Where
- 68 sites in United States, Argentina and 18 more
- Volunteers
- 1,472 people
- Sponsor
- Bayer
HIV
Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV
This Phase 3, single arm, multicenter study will evaluate the safety and effectiveness of ibalizumab in treatment-experienced patients infected with multi-drug resistant HIV-1.
- Trial name
- NCT02475629
- Testing
- ibalizumab, Optimized Background Regimen (OBR)
- Where
- 30 sites in United States, Puerto Rico and 1 more
- Volunteers
- 40 people
- Sponsor
- TaiMed Biologics Inc.
Pneumonia, Blood Stream Infection
Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)
Approximately 444 subjects who are greater than or equal to 18 to 95 years of age, are non-pregnant, and are in the inpatient setting of one of the study sites will be evaluated to treatment efficacy.
- Trial name
- NCT01597973
- Testing
- colistin and meropenem
- Where
- 19 sites in United States, Bulgaria and 5 more
- Volunteers
- 467 people
- Sponsor
- University of Michigan
Hypertension
Metabolic Effects of Antihypertensive Drugs on People With Metabolic Syndrome (The MEAD Study)
High blood pressure, also referred to as hypertension, is a blood pressure level of 140/90 mm Hg or higher. Along with lifestyle changes, various medications are currently used to treat people with hypertension.
- Trial name
- MEAD (NCT00887510)
- Testing
- Hydrochlorothiazide, Trandolapril
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Florida
Adrenal Cortex Neoplasms
Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer
This study will examine the safety and effectiveness of treating adrenocortical cancer with combination chemotherapy using doxorubicin, vincristine, and etoposide in addition to the drugs mitotane and tariquidar and, when…
- Trial name
- NCT00071058
- Testing
- XR9576 (Tariquidar)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
Diabetes Mellitus, Type 2
Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
Primary Objective: To evaluate equivalence of Gan \& Lee Insulin Glargine Injection and Lantus® in terms of immunogenicity Secondary Objective: Immunogenicity: To evaluate the percentage of subjects with negative anti-insulin…
- Trial name
- GLITTER 2 (NCT03371108)
- Testing
- Gan & Lee Insulin Glargine Injection, Lantus®
- Where
- 57 sites in United States
- Volunteers
- 567 people
- Sponsor
- Gan and Lee Pharmaceuticals, USA
GDM, Insulin Resistance
In Vitro Fertilization Impact on Metabolic Parameters
A quantitative prospective cohort study will be conducted, where blood samples will be collected at different timings during the IVF protocol, to assess the impact of fertility medications on metabolic parameters of patients…
- Conditions
- GDM, Insulin Resistance, Glucose Intolerance, PCOS
- Trial name
- IVF (NCT03426228)
- Testing
- HbA1C
- Where
- United Arab Emirates
- Volunteers
- 344 people, healthy volunteers welcome
- Sponsor
- University of Warwick
Hepatitis C, Medication Adherence
Smartphone Based aDOT Treatment With Fixed-Dose Elbasvir and Grazoprevir in PWIDs
People who Inject Drugs (PWIDs) constitute 60% of the approximately 5 million people in the United States infected with hepatitis C virus (HCV).
- Trial name
- NCT03127358
- Testing
- AiCure, AiCure with gamification
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Albert Einstein College of Medicine
Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer (mCRPC)
An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer
This is an open-label Phase II modular study in participants with prostate cancer which will assess safety, efficacy, and tolerability of AZD4635 in combination with other therapeutic agents in different treatment arms (referred…
- Trial name
- NCT04089553
- Testing
- AZD4635, Oleclumab, Durvalumab
- Where
- 9 sites in United States
- Volunteers
- 59 people
- Sponsor
- AstraZeneca
Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
This phase I trial investigates the side effects of cabozantinib and nivolumab in treating patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body…
- Conditions
- Advanced Differentiated Thyroid Gland Carcinoma, Advanced Head and Neck Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Kaposi Sarcoma
- Trial name
- NCT04514484
- Testing
- Biospecimen Collection, Cabozantinib S-malate, Computed Tomography
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Refractory Epilepsy
Modulation of Emotion Perception in Humans Via Amygdala Stimulation
This study will enroll patients with epilepsy who are being evaluated for epilepsy surgery and have intracranial EEG electrodes.
- Trial name
- NCT05292183
- Testing
- Electrical Stimulation
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer
This randomized phase II/III trial studies how well cediranib maleate and olaparib work when given together or separately, and compares them to standard chemotherapy in treating patients with ovarian, fallopian tube, or primary…
- Conditions
- Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma
- Trial name
- NCT02502266
- Testing
- Cediranib, Cediranib Maleate, Computed Tomography
- Where
- 398 sites in United States, Canada and 3 more
- Volunteers
- 582 people
- Sponsor
- National Cancer Institute (NCI)
Tuberculosis
High-Dose Isoniazid Among Adult Patients With Different Genetic Variants of INH-Resistant Tuberculosis (TB)
Isoniazid (INH) is a drug commonly used to treat tuberculosis (TB) worldwide. Sometimes, the bacteria that cause TB can become resistant to INH.
- Trial name
- NCT01936831
- Testing
- Isoniazid, Vitamin B6
- Where
- 2 sites in Haiti, South Africa
- Volunteers
- 282 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections